PhAc-ALGP-Dox

• Description:

  PhAc-ALGP-Dox, a peptide-drug conjugate, is a novel anticancer prodrug, with IC50 values ranged from 311 nM to 34.25 μM for TNBC (E0771), normal murine epithelium (HC-11), human TNBC (MDA-MB-231 and MDA-MB-468), human CrC (LS 174T), normal human epithelium (HME-1) cells[1].

• UNSPSC:

  12352209

• Target:

  Peptide-Drug Conjugates (PDCs)

• Type:

  Peptides

• Related Pathways:

  Antibody-drug Conjugate/ADC Related

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/phac-algp-dox.html

• Smiles:

  OC1=C(C(C2=CC=CC(OC)=C2C3=O)=O)C3=C(O)C4=C1C[C@](C(CO)=O)(O)C[C@@H]4O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)NC([C@H]6N(CCC6)C(CNC([C@H](CC(C)C)NC([C@H](C)NC(CP(O)(O)=O)=O)=O)=O)=O)=O

• Molecular Formula:

  C45H58N5O19P

• Molecular Weight:

  1003.94

• References & Citations:

  [1]Andrea Casazza, et al. PhAc-ALGP-Dox, a Novel Anticancer Prodrug with Targeted Activation and Improved Therapeutic Index. Mol Cancer Ther. 2022 Apr 1;21 (4) :568-581.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Peptides

• Clinical Information:

  No Development Reported

• CAS Number:

  1616592-31-4